Related references
Note: Only part of the references are listed.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features
Nicolino Ruperto et al.
ARTHRITIS AND RHEUMATISM (2012)
Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients
Justin Gillespie et al.
ARTHRITIS AND RHEUMATISM (2012)
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
Pierre Quartier et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Ongoing Disease Activity and Changing Categories in a Long-Term Nordic Cohort Study of Juvenile Idiopathic Arthritis
Ellen Nordal et al.
ARTHRITIS AND RHEUMATISM (2011)
Safety and Efficacy of an Oral Histone Deacetylase Inhibitor in Systemic-Onset Juvenile Idiopathic Arthritis
Jelena Vojinovic et al.
ARTHRITIS AND RHEUMATISM (2011)
Update on the pathogenesis and treatment of systemic idiopathic arthritis
Keith A. Sikora et al.
CURRENT OPINION IN PEDIATRICS (2011)
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Markus F. Neurath et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2011)
Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions
Elizabeth D. Mellins et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features
Timothy Beukelman et al.
ARTHRITIS CARE & RESEARCH (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
The safety profile of biologic therapies for juvenile idiopathic arthritis
Philip J. Hashkes et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis
P. Tynjala et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Successful treatment of resistant pseudogout with anakinra
Dennis McGonagle et al.
ARTHRITIS AND RHEUMATISM (2008)
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis
Marco Gattorno et al.
ARTHRITIS AND RHEUMATISM (2008)
How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets
Virginia Pascual et al.
IMMUNOLOGICAL REVIEWS (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Shumpei Yokota et al.
LANCET (2008)
Incidence and characteristics of arthritis in Norwegian children: A population-based study
Oystein Rolandsen Riise et al.
PEDIATRICS (2008)
IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17
M. Hashizume et al.
RHEUMATOLOGY (2008)
Interleukin 6: from bench to bedside
Norihiro Nishimoto et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Predictors of disease course and remission in systemic juvenile idiopathic arthritis - Significance of early clinical and laboratory features
D. Singh-Grewal et al.
ARTHRITIS AND RHEUMATISM (2006)
Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome
P Woo
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
V Pascual et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
A Ravelli et al.
JOURNAL OF PEDIATRICS (2005)
Therapeutic Efficacy of Humanized Recombinant Anti-Interleukin-6 Receptor Antibody in Children With Systemic-Onset Juvenile Idiopathic Arthritis
Shumpei Yokota et al.
ARTHRITIS AND RHEUMATISM (2005)
Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement
P Woo et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type
P Quartier et al.
ARTHRITIS AND RHEUMATISM (2003)
Humanized monoclonal anti-interieukin-6 receptor antibody for treatment of intractable adult-onset Still's disease
M Iwamoto et al.
ARTHRITIS AND RHEUMATISM (2002)
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
EHS Choy et al.
ARTHRITIS AND RHEUMATISM (2002)
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
N Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)
Share Paper
